Ixabepilone Administered as an Enteric Coated Formulation.

An Exploratory Study of Ixabepilone Administered as an Enteric Coated Formulation in Patients With Advanced Cancer.

The purpose of this study is to determine the pharmacokinetics of oral Ixabepilone.

Inclusion Criteria:

• ECOG status of 0-2.

Exclusion Criteria:

• Unable to swallow pills.
• Current or recent GI disease or GI surgery.
• Brain mets.
• Severe nerve damage.
• ANC <1,500/mm3
• Platelets <125K.
• Bilirubin >=1.5 times the IULN.
• ALT/AST >=1.5 times the IULN.
• Creatine >1.5 times the IULN.
• Prior treatment with Ixabepilone.
• Strong use of CYPP450 drugs.